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Occurrence of Cytomegalovirus Hepatitis 
in Liver Transplant Patients 
Oscar Bronsther, Leonard Makowka, Ronald Jaffe, A. Jake Demetris, 
Mary Kay Breinig, Monto Ho, Carlos O. Esquivel, Robert D. Gordon, 
Shunzaburo Iwatsuki, Andreas Tzakis, James W. Marsh, Jr., Vincenzo 
Mazzaferro, David Van Thiel, and Thomas E. Starzl 
Departments of Surgery. Pathology and Infectious Diseases and 
Microbiology, University of Pittsburgh Hea'th Center, University of 
Pittsburgh and the Veterans Administration Medical Center, Pittsburgh. 
Pennsylvania 
The differential diagnosis of liver dysfunction after ortholopic liver transplantation can 
be dIfficult Cytomegalovirus (CM\') hepatitis is one possibility. This report reviews 
our experience .... ith 17 cases of pathologicall~ proven CMV hepatitis follo .... ing liver 
transplantation and demonstrates the need for percutaneous liver biopsies to establish 
the diagnosis. There were seven pediatric patients (ages 2-11 years. five males. t .... o 
females) and ten adult patients (ages 17-53 years. eight males. two females). The most 
common symptoms were prolonged fever (15 patients. with a mean duration of 
22 ~ 5,5 days). elevation in total bilirubin (14 patients). and elevation in liver enzymes 
(15 patients): all symptoms .. ere also found in rejection. leUkopenia and thromboc),~ 
peOia. reponed to frequently occur with CMV infection. were found in only three and 
th'e pa lIents. respectively. 
T .... elve patients 110 ith the above symptoms underwent percutaneous biopsy on one or 
more occasIons to differentiate CMY hepalltis from rejection The diagnOSIS was made 
at retransrlantation in five patlenlS CMV hepatitIS follolloed treatment for acute 
rejection in 14 patienlS and oa::urred without additional immunosuppression in three 
patients All patients IIoere maintained on cyclosponne and prednisone, Acute rejection 
episodes were treated '" ith a 5-<lay tapering dose of steroids (17 courses in 12 patients). 
OKTJ monoclonal antibod~ [Ortho (4 patients)) antithymoc~1e globulin [Upjohn (2 
patienL~)). and azathioprine (1 patient), 
CM\ IIoas 1~lated from urine (nine patienL~). blood (nine patients). throat (se\'en 
patlcn15l. lungs (11100 pal1ents). and other organs (tlloo patients). CMY was cultured 
Aa:cplcd for publication Jul~ i. 1987. 
Add~ repnnl fcqU~ts 10 Dr Thomas E. St.lrzJ. Depanment of SUT@ef). 3601 Fifth Avenue. 4 W~t. Falk 
Clinic, Pittsburgh. Pennsylvania 15213. 
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from the Iivcr biopsy spc:cimcn~ in five of thc ~cn atlemrt~ in pediatric paticnL ... 
Whcn the dia~nor.i~ was confirm~ in the a~n<x of rcjcction. immun<Y.-upprcs.\ion wa~ 
routinely lowered. When rCJection occurred oonoomitantly with CM\' hcpatiti~. 
therap~ had to be individualized Retror.pcctivcl). thr« paticnL\ treated for rCJection 
wcrc noted al rctransplantation to havc onl) CM\' hcpatitis. and all three patlcnu 
died. 
A high indcx of suspicion and Ihe judicious usc of liver biopsies is c:s..<;ential in ordcr 
to differentiatc CMV hepatitis from othcr cau~ of posttransplanlliver dysfunction. 
INTRODUCTION 
The differentiation of liver dysfunction after orthotopic liver transplantation can be 
difficult. Possibilities include rejection. ischemic harvest injury. vascular thrombosis. bile 
duct complications. hemolysis. and hepatitis IStarz] et al. 1982; Esquivel et al. 1985]. The 
treatment is different for each possibility. and therefore there is a critical need to establish 
the correct diagnosis. One entity that has not received enough attention as both the cause 
of graft dysfunction. and significant morbidity and mortality is CMV hepatitis. To our 
knowledge. this is the first report to characterize and describe a series of patients with 
pathologically proven CMV hepatitis following orthotopic liver transplantation. On the 
basis of this review. recommendations for the diagnosis and management of CMV 
hepatitis during liver transplantation are presented. 
MATERIALS AND METHODS 
Between March. 1980 and September. 1985. after the advent of combined 
immunosuppression with cyclosporine and prednisone, 553 orthotopic liver transplants in 
429 patients were performed at the University of Pittsburgh. with the complete approval of 
the University's Institutional Review Board. 
More specific and aggressive management of rejection has resulted in improved 
patient and graft survival in an ever increasing patient population. One of the most useful 
adjuncts contributing to this improvement has been the evolution of a liberal policy of 
percutaneous liver biopsies. Biopsies are now routinely performed whenever there is 
clinical suspicion of acute rejection. and to help evaluate fever and biochemical abnormali-
ties when a diagnosis is not clear. 
The pathologic specimens from all patients undergoing orthotopic liver transplanta-
tion since 1980 were reviewed. Only those patients with pathologically proven CMV 
hepatitis were included in this analysis. 
Patients 
Seventeen patients. 13 males and 4 females, ranging in age from 2 years to 53 years. 
were identified. There were seven pediatric patients and ten adult patients. Eight of the 
patients had more than one transplant. Table I lists chronologically all of the patients 
diagnosed as having CMV hepatitis. A wide spectrum of pretransplant pathologic 
diagnoses existed in this group of patients, but the preoperative diagnosis was not 
prognostically significant (biliary atresia-four; primaf) biliary cirrhosis-two; alpha-
J -antitf)-psin deficiency-two; sclerosing cholangitis-two; idiopathic cirrhosis-two: 
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.. 21 Bron.~~ t1 aJ. 
Clinical specimen~ (throat. urine. buff~ coat. biopsy. or autopsy tissue) were 
inoculated into tube cultures of human foreskin fibroblasts (F7000. Flo" Laboratories. 
Mclean. V A) for isolation of CMV as pre\'iousl~ de.cribed IDummer et al. 1983]. These 
specimens are routinely cultured for CMV in all patients every 2 weeks during 
hospitaliza t ion. 
RESULTS 
Evaluation of Serology and Culture of CMV Infections (Table II) 
CMV infection is diagnosed by serologic changes and/or isolation of the virus. 
Primary CMV infections are diagnosed by seroconversion. Eight of the patients in this 
series had primary CMV infection. Three patients (Ol Tx #310. 472. 480) were 
seronegative prior to transplant and seroconverted after transplantation: pretransplant 
serology was not available on one patient (OL Tx 1481). but he was seronegative 
posttransplant and later seroconverted. Of the remaining four patients. all were seronega-
tive either pre- or posttransplants: later serum samples were not available to confirm 
seroconversion. 
Reactivation infection is diagnosed by a four-fold or greater rise in antibody titer. 
One patient had reactivation infection confirmed by a diagnostic rise. Five patients had 
"probable" reactivation infection. as indicated by seropositivity prior to and/or posttrans-
plant. although a diagnostic rise could not be demonstrated because samples were not 
available. In three patients, the presence of primaT) or reactivated CMV infection could 
not be determined due to a lack of appropriate serum samples. 
CMV was isolated from one or more specimens (i.e .• blood, urine. throat) in 15 of the 
17 patients. The associated bacterial and fungal infections found in these patients are also 
listed in Table II. 
Evaluation of Clinical Signs and Symptoms 
Table III summarizc:s the fever and hepatic function profiles for these patients. 
Fifteen of 17 patients had fever for more than 5 days. with a range of 5-68 days and a 
mean of 22 !: 5.5 days. One patient was afebrile throughout the course of the disease. and 
one patient had fever for a single day. The highesr temperatures ranged from 38.5OC to 
4O.5°C. and in some patients. fever persisted after the resolution of biochemical 
abnormalities. 
Bilirubin was elevated in 14 of the 17 patients. When the diagnosis was established 
at retransplantation, bilirubin was substantially higher than when the diagnosis was 
established by biopsy. The highest values of 44 mgjdl and 20.4 mg/dl occurred in patients 
undergoing retransplantation with simultaneous CMV hepatitis and ischemic injury. 
SGOT was elevated in 16 of J7 patients at diagnosis and continued to rise after 
diagnosis in 8 patients. Most elevations were in the 100-300 It.: range. but in three 
patients. values were greater than 700 IU. SGPT was elevated in 16 of 17 patients and 
continued to rise in 6 patients after the diagnosis "'as established. Most values were in the 
50-200 IU range. and five values were greater than 400 IU. It is of that note only three 
patients developed leukopenia (",hite blood cell count of less than 3.000). and only five 
patients developed thrombocY1openia (platelet count less than 100,000). 
Evaluation of Management 
The management of CM\' hepatitis has been altered by our increasing use of 
percutaneous liver biopsies. In our series of 17 patients. 5 of the first 8 patients having 
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T A Bl£ nt. Clinical Silft" and S) mpcOft1.\ or ("ytomtplo, inI.\ JWp.titis· 
Ft'ler 
OLTx Duralion HI,he.<>1 Bilirubin (m,ldl) SGOl (lL) SGPT (I L ) -------.-
no. (da\'\) (ee) On 81 dale HI,hc.\1 On 8\ dale HI,hcst On 81 date Hi~hc.\t 
203 3~ 38~ 4.4 44 157 157 49 49 
213 22 394 49 4.9 282 282 486 486 
257 20 38~ 20.4 30 188 441 263 802 
291 17 39.8 
292 20 39.3 1.7 1.7 27 321 131 131 
310 3~ 39.2 4.6 4.6 1103 1103 470 470 
334 22 39 6.2 12.4 274 759 333 405 
348 5 39 9.0 9.0 266 443 111 292 
390 7 39 8.t> 27.2 121 4~3 89 89 
393 Afebrile 2.7 4.6 203 203 140 140 
394 68 39.5 0.7 1.3 160 185 67 76 
4~ 11 39 0.\ 0.7 58 58 40 40 
472 25 4O.~ 2.7 5.3 745 74~ 588 588 
480 24 39 09 16.8 72 746 58 332 
481 I 38.8 2.5 5.4 78 153 63 112 
514 23 40 0.7 0.7 163 163 159 159 
556 14 39.5 2.1 2.3 72 85 56 69 
·OL Tx no .• orthotopiC liver transplant. 8x. biopsy. 
CMY hepatitis were only diagnosed at the time of retransplantation; therefore only 3 of 
these first 8 patients were diagnosed by biopsy. However. all of the last nine patients to be 
diagnosed as having CMY hepatitis were diagnosed by percutaneous biopsy. The use of 
percutaneous biops~ significantly facilitates the establishment of the diagnosis of CMY 
hepatitis and fa"'orably influenced patient survival in this series. Only 4 of the 12 patients 
diagnosed by biopsy have died, whereas 4 of 5 patients who were unexpectedly diagnosed 
at retransplantation have died. 
When the diagnosis of CMV hepatitis was established by biopsy and no rejection 
was present. the management was the reduction of cyclosporine and/or prednisone (eight 
patients). In one other such patient. there was no reduction in maintenance immunosu~ 
pression. In most patients. cyclosp:)rine was lowered in order to achieve R I A levels of 
300-400 ng/per dL Maintenance prednisone doses were reduced to 5. 10, or 15 mgjday. 
Difficulty in patient management arose when a biopsy revealed concurrent CMY 
hepatitis and rejection. This occurred in four patients (OLTx 291. 394. 481,and 514). and 
it required careful individualization of management. It was always necessary to treat the 
rejection comp:)nent. and it was not uncommon to find worsening of the CMV hepatitis 
after therapy for rejection. Following resolution of rejection. immunosuppression had to be 
closely monitored and conceivably lowered to allo" resolution of the CMV hepatitis. 
The "orst outcome was evident in a group of patients who underv.ent retransplanta-
tion with the diagnosis of endstage rejection but who in fact had CMV hepatitis with no 
rejection at the time of retransplantation. All three of these patients (OL Tx 203,257,348) 
ultimately expired. 
Three patients (OL Tx 480, 514, and 556) were recognized as having CMV hepatitis 
prior to receiving therapy for acute rejection. Therefore. 3 of 17 patients developed CMY 
hepatitis with no treatment for rejection, and 14 of 17 patients had from one to four 
courses of treatment for acute rejection prior to developing CMY hepatitis. These are 
summarized in Table I. 
Bronsthrr d aJ. 
, Fi, I. AI ViTally transrormed ~JIs are \ar~. with nuclear inclusions noted in some sections. but cytoplasmic 
chang~ are visible (arro.,.) even ""here nuclear inclusions arc not e--ident (HIE )( 198). B'lmmunopcroxidasc 
staining usin& anti-CMV antibod) reveals the presenc:c or cytoplasmic antigen. the nuclear inclUSIOn being 
unstained (DAB)( 257). 0 CMV antigen can be detected in degenerating ~II rragmcnu engulred by 
neutrophils. 5«n here I.S dark precipitate (aITO\\s) (DAB )( 265). 
Evaluation of Biopsies and Differentiation from Rejection (Table I) 
Clusters of neutrophils. often forming a microabscess within the lobule. were a clue 
to the presence of eMV. and their presence sparked a search for the virus. Virus was found 
almost entirely within hepatocytes. more rarely in Kupfer cells. endothelial cells. or biliary 
epithelium. In adults. where concomiLant ischemic changes were more common. virus was 
noted to be in periportal hepatoc),les and Kupfer cells as well as in biliaT) epithelial cells. 
Rapidly dividing cells in granulation tissue around abscesses or at anastomotic lines 
appeared to be particularly vulnerable. These cells were often heavily involved. while 
surrounding tissues were devoid of CMV. Neutrophil aggregates were less prominent in 
adults. in whom mononuclear cells were more conspicuous. 
Infestation varied markedly. from 0.2 to 23 infected cells per mm2 of tissue. 
Hematoxylin·eosin proved as sensitive for the diagnosis as anti·CMV antibody Staining of 
viral antigen using the anti·CMV antibody demonstrated cytoplasmic virus only in those 
cells displaying CYlopathic effect. In no instance was unsuspected infection demonstrated 
by use of the antibody alone. However. the neutrophil clusters often surrounded cell debris 
in which CMV antigen was detectable. even through no inclusions were noted (Fig. I). 
The presence and severity of other concomitant processes could be assessed 
independently of the eMV hepatitis. Inflammation in the hepatitis was limited to 
neutrophils and mononuclear cells in close contact with virally infected cells. Rejection 
could be independently e\'a)uated and was absent in five patients and present ..... ith varying 
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Fig 2 eM\ is independent of the amoont of rejection AI The portal area (p) sho"s oomplete absence or 
inflammator~ cells A lobular mlcroobs..::c:..< surroond~ a \o'irall~ anfected cell (arro") (HIE x 120). BI hpanded 
and infiltrated portal area (p) charactem"c of rejection is pre:loCnt In this biops~. In "h,ch virall~ transrormed 
celh are ",sible In the lobule (arro") (H:E )< 114) 
4)2 Bron.qMr ft aI. 
degr~ of ~verity in 12. There wa~ no rdationship between the extent of the: CMY 
infestation and the severity of the rejection changc-5- (Fig 2). 
DISCUSSION 
Although CMY hepatitis has been well rerognized in both the normal and the 
immunocompromised host. this is the first report to describe this entity as a recurrent 
problem in orthotopic liver transplantation. While hepatitis is oommon in CMY infections. 
it is usually not severe. even in other types of transplant patients (Ten Napel et al. 1984). 
Unique concerns arise when CMY infection associated with abnormalities in bilirubin and 
liver enzymes occur following liver transplantation The differential of liver dysfunction 
after orthotopic liver transplantation includes rejection. ischemic injury. vascular throm-
bosis. bile duct complications. hemolysis. and hepatitis. 
CMV hepatitis arises relatively late after liver transplantation (15-132 days. with a 
mean of 44 ~ 6 days) and virtually always is accompanied by prolonged fever (15 of 17 
patients. with a mean duration of fever of 22 :! 5.5 days). Practically. this means that. the 
critical differentiation is between hepatitis and rejection. The quickest and most definitive 
means of discriminating between these two entities is a percutaneous liver biopsy. We 
established the diagnosis of CMV hepatitis in the last nine patients by percutaneous 
biopsy. while we established the diagnosis at retransplantation in five of the first eight 
patients. This difference arose in our series becluse we have liberalized our policy 
concerning percutaneous biopsies in the last I to :! years. When the diagnosis was first 
established al retransplantation. four of the five patients diagnosed in this manner died. 
while only 4 of 12 patients diagnosed on percutaneous biopsy have died. Other reports have 
attempted to document CMV hepatitis in immunocompromised patients. such as kidney. 
heart. heart·lung. and bone marrow transplant recipients [Dummer et al. 1983; Ho 1983]. 
But few of these reports have histopathologic confirmation of the diagnosis of CMV 
hepatitis. whereas the histologic confirmation of this diagnosis was obtained in all of the 
patients in this series. In addition to histologic confirmation. the CMV virus was cultured 
in five pediatric and one adult liver specimens. CMY was isolated on culture of other sites 
in 15 of the 17 patients. The timing of these isolations. however. was not alway~ clinically 
useful. as viral cultures can take 2 to 3 weeks. and frequently the cultures 'Were not positive 
until after we had established the diagnosis on biopsy or retransplant. Infection is 
froquently asymptomatic [Ho et al. 1983]. Hence these cultures are insufficient evidence 
for the diagnosis of CMV hepatitis. 
Interestingly. patients with both primary and reactivation infections developed 
CMY hepatitis. and the patients' pretransplant serologic status was not prognostically 
significant. Eight patients with CMV hepatitis had primary CMV infection. and in six 
patients. the hepatitis followed eMV reactivation. We were unable to interpret the 
serologic data in three patients. The rate of primary CMV infections among liver 
transplant recipients is reported to be 289C IHo et al. 1983]. As 579C of our patients 
de\'eloped hepatitis following a primary CMV infection. this suggests that patients with a 
primaf) infection are at greater risk for developing hepatitis. In eight patients with 
primary CMV infection. there were three deaths. and five patients survived. In the six 
patients wilh reacti\·ated disease. there were three deaths and three survivors. Also. the site 
of CMV isolation. namely in the blood. has been reported to be an indicator of more severe 
or Iife·threatening infection [Armstrong et al. 1971; Pass el al. 1980]. This did not prove to 
be the case in the analysis of the present patient group. 
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The management of th~ patient!. ha!o C"olved a<. v.e have oome to be more a .... are of 
the entity. In at lea~t three cases. patient<. underwent retran<.rlantation for an incorrect 
diagnosis The liver function abnorm<llitic. .. were thought to rerr~nt endstage rejection in 
these patients. v.hereas the pathology demonwated the a~nce of rejection and the 
presence of CMY hepatiti~ In most in!'tance~. CMV hepatitis is re\er~ible with the 
reduction of immunosuppressIon. 
The diagnosis of CMV hepatiti!o was made .... hen a single v'iral inclusion was 
identified. Infestalion v. as seen to increase markedl) in some instances when concomitant 
rejection was aggressivel) treated. Because the inflammatory response provoked by the 
CMY was localized to the infected cells. there was very little overlap with other 
simultaneous processes. In particular. the portal inflammatory profile characteristic or 
rejection was not provoked by the CMV hepatitis alone. Severe hepatitis .... ith hea\') 
infestation was nOled without portal infiltrate of any degree. even though it must be 
recognized that antirejection therapy can alter the cellular profile of the rejection 
response. 
Starr et a111984] have shown that the natural killing against CMV-infected target 
cells was depressed in kidney recipients for 2 years after transplantation but that a 
reduction in immunosuppression in these patients resulted in temporal association with 
resolution of CMY disea~. In addition. CMV is felt to be an immunosuppressive agent on 
its own. and therefore. if full-maintenance immunosuppression is maintained during the 
course of the disea~. the patient may in fact be over-immunosuppressed and susceptible to 
additional bacterial or opportunistic infections. 
At present. when a diagnosis of CMY hepatitis is established in a liver transplant 
recipient in whom there is no evidence of rejection. our management is to lower the d~ of 
cyclosporine and/or prednisone. With the confirmation ofCMV hepatitis. the therapeutic 
levels of cyclosporine of 700-1.000 ns/dl are usually lowered 10 300-400 ng/d!. When 
there is clinical resolution of the hepatitis. cyclosporine is then returned to therapeutic 
levels. Prednisone is usually lowered from maintenance at 20 mg/day to 5. 10. or 15 
ms/day depending on the clinical ~verity of the di5ea~ (in children. the dose is frequently 
lowered even rurther). A problem arises in the management of patients who have 
concomitant CMV infection and rejection. as occurred in four patients. In this group of 
patients. our initial concern is directed toward the treatment of rejection. Ho .... ever. as we 
treal rejection. it is not uncommon that the eMV hepatitis worsens. and after resolution of 
rejection. we frequentl) have to deal ..... ith the CMV hepatitis. This may require the 
reduction in the maintenance levels of immunosuppression until the CMV disea~ has 
resolved: full-maintenance immunosuppression is then resumed . 
CM V hepatitis afler orthotopic liver transplantation is a definite clinical entity with 
specific signs and symptoms. ~rologic and culture findings. and pathologic features; it is 
being recognized with increased frequency in both adult and pediatric patients. The 
differentiation ofCM\' hepatitis from other causes of liver dysfunclion is essential in order 
to institute appropriate management. Currentl) it is best achieved b) a high index of 
suspicion and the Judicious u~ of liver biopsies. 
We ha\·e. for the past tv.o years used a monoclonal antibody to earl) intermediate 
CMY antigen (Chemican. EI Segundo. CA) ..... hich can. after trypsin digestion. demon-
strate nuclear antigen before infected cells are morphologically transferred. It is thus 
possible to make the diagnosis of CMY on biops) of an apparently uninvolved specimen. 
This ha~ not changed an) of the conclusions presented in this paper. 
4..\4 Br()fl~hu '" al. 
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